



## IPO : Q-Line Biotech Limited

May 2026

**Snapshot**

Q-Line Biotech Limited is an India-based biotechnology and healthcare company focused on manufacturing, marketing, and distribution of pharmaceutical and biotech products. The company operates with an emphasis on quality healthcare solutions, serving hospitals, laboratories, and medical institutions across multiple regions. It aims to strengthen its market presence through innovation, product diversification, and customer-centric services. With a growing distribution network and experienced management team, the company is working to expand its operational scale and improve brand recognition in the healthcare sector. Q-Line Biotech plans to utilize its IPO proceeds for business expansion, working capital requirements, and overall corporate growth initiatives.

**Company Vision**

Q-Line Biotech Limited envisions becoming a trusted and innovative healthcare and biotechnology company by delivering high-quality pharmaceutical and biotech products that improve healthcare accessibility and patient outcomes. The company aims to strengthen its presence across domestic and international markets through continuous product development, advanced technology adoption, and efficient distribution systems. It focuses on building long-term relationships with customers, healthcare institutions, and business partners while maintaining strong ethical and quality standards. Q-Line Biotech aspires to achieve sustainable growth by expanding its product portfolio, enhancing operational efficiency, and creating value for stakeholders through innovation, reliability, and customer-focused healthcare solutions.

**Growth Prospects**

Q-Line Biotech Limited has promising growth prospects driven by increasing demand for healthcare and biotechnology products in India and global markets. The company's focus on expanding its product portfolio, improving distribution reach, and strengthening customer relationships can support long-term business growth. Rising healthcare awareness, technological advancements, and growing investments in the pharmaceutical and biotech sectors create favorable opportunities for expansion. The company also plans to utilize IPO proceeds for working capital and operational development. With experienced management and a focus on quality standards, Q-Line Biotech is positioned to capitalize on emerging opportunities in the healthcare industry.

Opening Date	Thursday, May 21, 2026
Closing Date	Monday, May 25, 2026
Price Band	Rs. 326 to Rs. 343 per share
Bid Lot	400 Shares
Face Value	Rs. 10 per share
Issue Size	62,53,200 shares (aggregating up to Rs. 214 Cr)
Reserved for Market Maker	3,13,200 shares (aggregating up to Rs. 11 Cr)
Fresh Issue	59,40,000 shares (aggregating up to Rs. 204 Cr)
Registrar	Purva Shareregistry (India) Pvt.Ltd.

**Key Financials**

	Key Financial			
	Amount in cr.	Dec-2025	FY2025	FY2024
Assets	561.34	455.49	339.25	251.58
Total Income	236.50	322.58	206.45	184.81
Profit After Tax	38.69	28.13	34.44	32.10
EBITDA	64.23	71.32	37.63	32.98
NET Worth	-0.04	189.95	161.81	127.37
Reserves and Surplus	2,12,88,920	188.37	160.24	125.79
Total Borrowing	243.85	164.95	96.91	73.65

**Risk Assessment**

Q-Line Biotech Limited faces several business risks that could impact its future performance and profitability. The company operates in a highly competitive pharmaceutical and biotechnology industry where pricing pressure, changing customer preferences, and competition from larger established players may affect growth. Regulatory compliance requirements and changes in healthcare policies can also increase operational challenges and costs. Dependence on suppliers, distribution networks, and working capital availability may influence business continuity. Additionally, fluctuations in raw material prices and economic uncertainties could impact margins. Any failure to maintain product quality standards or expand market presence may adversely affect the company's reputation and financial stability.